Equities analysts forecast that Nuvectra Corp (NASDAQ:NVTR) will report earnings per share (EPS) of ($0.81) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Nuvectra’s earnings. The highest EPS estimate is ($0.78) and the lowest is ($0.84). Nuvectra posted earnings of ($0.83) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 2.4%. The firm is scheduled to announce its next earnings report after the market closes on Wednesday, July 31st.
According to Zacks, analysts expect that Nuvectra will report full-year earnings of ($3.18) per share for the current fiscal year, with EPS estimates ranging from ($3.35) to ($3.00). For the next year, analysts anticipate that the firm will post earnings of ($2.12) per share, with EPS estimates ranging from ($2.53) to ($1.71). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for Nuvectra.
Nuvectra (NASDAQ:NVTR) last released its earnings results on Wednesday, May 1st. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.18). Nuvectra had a negative return on equity of 62.18% and a negative net margin of 98.77%. The business had revenue of $11.13 million for the quarter, compared to analyst estimates of $12.76 million.
Several equities analysts have issued reports on the company. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday, July 10th. ValuEngine upgraded Yirendai from a “strong sell” rating to a “sell” rating in a research report on Friday, May 3rd. Finally, JMP Securities boosted their target price on Qualys from $85.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 2nd. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Nuvectra currently has an average rating of “Hold” and a consensus target price of $15.00.
NASDAQ NVTR traded up $0.03 on Thursday, hitting $2.06. 251,190 shares of the company’s stock were exchanged, compared to its average volume of 292,148. The company has a current ratio of 6.60, a quick ratio of 6.07 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $3.20. Nuvectra has a fifty-two week low of $2.01 and a fifty-two week high of $25.17. The stock has a market cap of $37.92 million, a price-to-earnings ratio of -0.64 and a beta of 0.74.
In related news, Director David D. Johnson bought 20,000 shares of the stock in a transaction on Monday, May 6th. The shares were purchased at an average price of $6.12 per share, for a total transaction of $122,400.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, President Joseph Paul Hanchin sold 7,900 shares of the stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $3.98, for a total value of $31,442.00. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.
Large investors have recently made changes to their positions in the business. Edge Wealth Management LLC grew its position in Nuvectra by 89.9% in the second quarter. Edge Wealth Management LLC now owns 40,140 shares of the company’s stock valued at $133,000 after purchasing an additional 19,000 shares in the last quarter. Marshall Wace LLP bought a new position in Nuvectra in the first quarter valued at $1,155,000. Meitav Dash Investments Ltd. acquired a new stake in Nuvectra in the first quarter valued at $2,377,000. Thompson Siegel & Walmsley LLC acquired a new stake in Nuvectra in the first quarter valued at $64,000. Finally, Rockefeller Capital Management L.P. lifted its stake in Nuvectra by 0.7% in the first quarter. Rockefeller Capital Management L.P. now owns 435,548 shares of the company’s stock valued at $4,795,000 after acquiring an additional 2,968 shares during the last quarter. Hedge funds and other institutional investors own 80.36% of the company’s stock.
Nuvectra Company Profile
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
See Also: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.